ESPE2022 Poster Category 2 Adrenals and HPA Axis (27 abstracts)
Objective: To assess the efficacy and influential factors of GnRHa treatment for Chinese CPP/EFP boys.
Methods: From April, 1994 to June, 2020, 94 boys diagnosed with CPP or EFP who had reached the final adult height were retrospectively included. Among these patients, 41 patients received no treatment, 43 patients received GnRHa treatment alone and 10 patients received GnRHa + GH treatment. The final adult height and the demographic data during the treatment were obtained.
Results: The bone age on the initial of the treatment was relatively old (>12y) compared with girls, only 1/43 patients in the GnRHa group, 1/10 patients in the GnRHa+GH group and 1/41 patients in the no treatment group was younger than 12 years. Higher PAH was observed after treatment in both GnRHa group and the GnRHa+GH group (PAH2 - PAH1 = 4.03 ± 5.36 cm vs. 7.61 ± 4.60 cm). The FAH (170.41 ± 5.78 cm in GnRHa group, 168.80 ± 7.69 cm in GnRHa+GH group and 170.19 ± 6.28 cm in no treatment group, P > 0.05) showed no significant difference among three groups. GnRHa+GH group showed significant larger height gain (FAH-PAH1) in comparison with GnRHa and no treatment groups (GnRHa+GH 4.3 ± 2.60 cm vs. GnRHa 1.21 ± 4.47 cm, post hoc P< 0.05, GnRHa+GH vs. no treatment 1.03 ± 4.50 cm, post hoc P< 0.05), while there was no significant difference between GnRHa group and no treatment group. In the 7th-12th months, both of the GnRHa group and GnRHa+GH group GV< 5 cm/y, but the height gain of GnRHa group showed no significance compared to the no treatment group. ΔBA/ΔCA during treatment was significantly negatively correlated with height gain. If ΔBA/ΔCA<0.624, the height gain probably < 0 cm.
Conclusion: GnRHa treatment could significantly inhibit the gonadal axis and bone maturation. But For Chinese CPP/EFP boys with relatively old bone age (> 12 y), GnRHa alone could not benefit for the height gain compared with the no treatment group, especially when PAH > THt, △BA/△CA > 0.624 and GV< 5 cm/y during treatment, while the GnRHa+GH treatment significantly improve the height gain.
15 Sep 2022 - 17 Sep 2022